 BOSTON, Nov. 08, 2021 GLOBE NEWSWIRE -- Decibel Therapeutics Nasdaq: DBTX, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced its participation in the fifth annual Barclays Gene Editing Gene Therapy Summit on Monday, November 15, 2021. Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at 3:30 pm ET and in a panel discussion titled Addressing Development Challenges and the Regulatory Hurdles at 4:45 pm ET. 